For secondary prevention in higher risk patients** who are willing to intensify treatment, we suggest adding ezetimibe to either moderate- or high-dose statins for reducing non-fatal cardiovascular events following a discussion of the risks, additional benefits, and an exploration of the patient s values and preferences. Weak for Reviewed, New- replaced 14. For secondary prevention in higher risk patients** who are willing to intensify treatment, we suggest offering a PCSK9 inhibitor in addition to a maximally tolerated statin dose with ezetimibe for reducing non-fatal cardiovascular events following a discussion of their uncertain long-term safety, additional benefits, and an exploration of the patient s values and preferences. Weak for Reviewed, New- replaced c. Other Medications, Supplements, and Nutraceuticals 15. For primary or secondary prevention, we recommend against using niacin (i.e., supplements or prescriptions). Strong against Reviewed, New- replaced 16. For primary or secondary prevention, we suggest against adding fibrates to statins. Weak against Reviewed, New- replaced 17. There is insufficient evidence to recommend for or against using bempedoic acid with or without statins for either primary or secondary prevention. Neither for nor against Reviewed, New- added 18. For primary prevention, there is insufficient evidence to recommend for or against icosapent ethyl in patients on statin therapy with persistently elevated fasting triglycerides. Neither for nor against Reviewed, New- added 19. For secondary prevention, we suggest offering icosapent ethyl in patients on statin therapy with persistently elevated fasting triglycerides >150 mg/dL to reduce cardiovascular morbidity and mortality. Weak for Reviewed, New- added 20. For primary or secondary prevention, we suggest against the use of omega-3 fatty acids as a dietary supplement to reduce cardiovascular disease risk. Weak against Reviewed, New- added 21. 